Tcg Crossover Management, LLC Geron Corp Transaction History

Tcg Crossover Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.75 - $3.44 $10.5 Million - $20.6 Million	-5,984,200 Reduced 25.6%	17,391,639 $57.4 Million
Q3 2023 Nov 14, 2023	SELL	$2.11 - $3.28 $451,413 - $701,723	-213,940 Reduced 0.91%	23,375,839 $49.6 Million
Q2 2023 Aug 14, 2023	BUY	$1.97 - $3.69 $11.5 Million - $21.5 Million	5,824,566 Added 32.79%	23,589,779 $75.7 Million
Q1 2023 May 15, 2023	BUY	$2.14 - $3.4 $5.52 Million - $8.77 Million	2,578,140 Added 16.98%	17,765,213 $38.6 Million
Q4 2022 Feb 14, 2023	BUY	$2.03 - $2.42 $6.23 Million - $7.43 Million	3,071,147 Added 25.35%	15,187,073 $36.8 Million
Q3 2022 Nov 14, 2022	SELL	$1.67 - $2.94 $4.98 Million - $8.76 Million	-2,980,416 Reduced 19.74%	12,115,926 $28.4 Million
Q2 2022 Aug 15, 2022	BUY	$1.19 - $1.65 $964,646 - $1.34 Million	810,627 Added 5.67%	15,096,342 $23.4 Million
Q1 2022 May 16, 2022	BUY	$0.99 - $1.6 $14.1 Million - $22.9 Million	14,285,715 New	14,285,715 $19.4 Million

275

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.51B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Tcg Crossover Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Tcg Crossover Management, LLC with notifications on news.